Sovaprevir
Appearance
![]() | |
Clinical data | |
---|---|
Other names | ACH-1625 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C43H53N5O8S |
Molar mass | 799.98 g·mol−1 |
3D model (JSmol) | |
| |
|
Sovaprevir (codenamed ACH-1625) is an experimental drug designed to treat the hepatitis C virus. It is under development by Achillion Pharmaceuticals. It acts as a NS3/4A inhibitor.[1] Sovaprevir received fast track status from the U.S. Food and Drug Administration in 2012.[2]
References
[edit]- ^ De Clercq E (June 2014). "Current race in the development of DAAs (direct-acting antivirals) against HCV". Biochemical Pharmacology. 89 (4): 441–52. doi:10.1016/j.bcp.2014.04.005. PMID 24735613.
- ^ "Sovaprevir HCV NS3/4A Protease Inhibitor". Achillion.